Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

Revance Therapeutics CEO and leadership

Zippia score 4.2
Job openings (51)
OverviewJobsSalaryRevenue

Reviews

DemographicsCompetitors

CEO & Executives

Revance Therapeutics CEO and executives

Executive Summary. Based on our data team's research, Mark J. Foley is the Revance Therapeutics's CEO. Revance Therapeutics has 170 employees, of which 30 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Revance Therapeutics executive team is 37% female and 63% male.
  • 64% of the management team is White.
  • 13% of Revance Therapeutics management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Work at Revance Therapeutics?
Share your experience

Rate Revance Therapeutics' leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
Mark J. Foley

President/CEO

Mark J. Foley's LinkedIn

Experienced MedTech Executive with 25+ years of experience including roles as a senior executive, CEO (public and private companies), Founder/entrepreneur, Venture Capitalist and Board Member/Executive Chairman/Chairman. Served as Chairman, President and Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) from April of 2012 until the Company's acquisition by Allergan for $2.5B in April of 2017. Initially, I joined ZELTIQ in 2009 as Executive Chairman and as a member of the Board of Directors. Currently, I am a Managing Director at RWI Ventures, serve as Chairman of the Board for ULab, HintMD and Arrinex and am a board member at Glaukos (GKOS) and Revance (RVNC). Prior to this, I served on the boards of several private companies, held operating roles in large, public companies and venture-backed start-ups including US Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where I was the founder and CEO. I received my B.A. from the University of Notre Dame (1987) and am a named inventor on 17 patent applications.

Jacob Waugh

Founder

L. Daniel Browne

Founder

Dwight Moxie

Senior Vice President, General Counsel and Corporate Secretary

Dwight Moxie's LinkedIn

Justin Ford

Vice President-Human Resources & Head-People

Justin Ford's LinkedIn

Tobin C. Schilke

Chief Financial Officer

Tobin C. Schilke's LinkedIn

Angus C. Russell

Non-Executive Chairman

Azita Nejad

Senior Vice President

Azita Nejad's LinkedIn

Carey O’Connor Kolaja

Board Member

Christian W. Nolet

Chair

Do you work at Revance Therapeutics?

Does leadership effectively guide Revance Therapeutics toward its goals?

Revance Therapeutics jobs

Revance Therapeutics founders

Name & TitleBio
Jacob Waugh

Founder

L. Daniel Browne

Founder

Revance Therapeutics board members

Name & TitleBio
Mark J. Foley

President/CEO

Mark J. Foley's LinkedIn

Experienced MedTech Executive with 25+ years of experience including roles as a senior executive, CEO (public and private companies), Founder/entrepreneur, Venture Capitalist and Board Member/Executive Chairman/Chairman. Served as Chairman, President and Chief Executive Officer of ZELTIQ Aesthetics (ZLTQ) from April of 2012 until the Company's acquisition by Allergan for $2.5B in April of 2017. Initially, I joined ZELTIQ in 2009 as Executive Chairman and as a member of the Board of Directors. Currently, I am a Managing Director at RWI Ventures, serve as Chairman of the Board for ULab, HintMD and Arrinex and am a board member at Glaukos (GKOS) and Revance (RVNC). Prior to this, I served on the boards of several private companies, held operating roles in large, public companies and venture-backed start-ups including US Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic) where I was the founder and CEO. I received my B.A. from the University of Notre Dame (1987) and am a named inventor on 17 patent applications.

Angus C. Russell

Non-Executive Chairman

Carey O’Connor Kolaja

Board Member

Christian W. Nolet

Chair

Jill Beraud

Board Member

Julian S. Gangolli

Board Member

Olivia C. Ware

Board Member

Philip J. Vickers

Board Member

Robert Byrnes

Board Member

Phyllis Gardner

Board Member

Revance Therapeutics leadership demographics

Revance Therapeutics gender distribution in management team

  • The Revance Therapeutics executive team is 37% female and 63% male.
  • Revance Therapeutics is 50% female and 50% male company-wide.
Male
Male
63%
Company-wide: 50%
Female
Female
37%
Company-wide: 50%

Revance Therapeutics executives by race

Management Team:
  • The most common ethnicity among Revance Therapeutics executive officers is White.
  • 64% of the management team is White.
  • 13% of Revance Therapeutics's management is Hispanic or Latino.
  • 10% of the management team is Black or African American.
Company-wide:
  • White is the most common ethnicity company-wide.
  • 37% of employees are White.
  • 26% of employees are Asian.
  • 25% of employees are Hispanic or Latino.
  • Management team
  • General
100%
80%
60%
40%
20%
0%
Unknown
White
Black or African American
Asian
Hispanic or Latino

Revance Therapeutics jobs nearby

Revance Therapeutics executives FAQs

Related company executives

Working at related companies

Related company jobs

Revance Therapeutics highest paying jobs

Updated November 18, 2022

Zippia gives an in-depth look into the details of Revance Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Revance Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Revance Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Revance Therapeutics. The data presented on this page does not represent the view of Revance Therapeutics and its employees or that of Zippia.

Revance Therapeutics may also be known as or be related to REVANCE THERAPEUTICS INC., Revance Therapeutics, Revance Therapeutics Inc and Revance Therapeutics, Inc.